EP0690840A1 - Novel distamycin analogues - Google Patents

Novel distamycin analogues

Info

Publication number
EP0690840A1
EP0690840A1 EP94909068A EP94909068A EP0690840A1 EP 0690840 A1 EP0690840 A1 EP 0690840A1 EP 94909068 A EP94909068 A EP 94909068A EP 94909068 A EP94909068 A EP 94909068A EP 0690840 A1 EP0690840 A1 EP 0690840A1
Authority
EP
European Patent Office
Prior art keywords
pyrrol
methyl
carboxyamido
chloroethyl
bis
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP94909068A
Other languages
German (de)
French (fr)
Inventor
Fabio Animati
Paolo Lombardi
Cristina Rossi
Giuseppe Giannini
Giovanna Di Pietro
Federico Arcamone
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Menarini Industrie Farmaceutiche Riunite SRL
Bristol Myers Squibb SpA
Original Assignee
Menarini Industrie Farmaceutiche Riunite SRL
Bristol Myers Squibb SpA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Menarini Industrie Farmaceutiche Riunite SRL, Bristol Myers Squibb SpA filed Critical Menarini Industrie Farmaceutiche Riunite SRL
Publication of EP0690840A1 publication Critical patent/EP0690840A1/en
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
    • C07C237/28—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a non-condensed six-membered aromatic ring of the carbon skeleton
    • C07C237/36—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a non-condensed six-membered aromatic ring of the carbon skeleton having the nitrogen atom of the carboxamide group bound to an acyclic carbon atom of a hydrocarbon radical substituted by carboxyl groups
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
    • C07C237/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C237/04—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C237/10—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated having the nitrogen atom of at least one of the carboxamide groups bound to an acyclic carbon atom of a hydrocarbon radical substituted by nitrogen atoms not being part of nitro or nitroso groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
    • C07C237/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C237/14—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being saturated and containing rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
    • C07C237/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C237/20—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton containing six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
    • C07C237/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C237/22—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton having nitrogen atoms of amino groups bound to the carbon skeleton of the acid part, further acylated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
    • C07C237/24—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a ring other than a six-membered aromatic ring of the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D207/34—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms

Definitions

  • n is 0 or an integer ranging from 1 to 4 is 0 or an integer ranging from 1 to 4 A is selected from the group consisting of : acyclic, aromatic or heterocyclic residue
  • B is selected from the group consisting of : a simple chemical bond, -C0-NH-CH(R 3 )-, -NH-C0-CH(R 3 )- wherein R ⁇ is H or the side chain of a natural alpha-aminocarboxylic acid;
  • Antibiotic dystamicine is a known compound of formula (II) :
  • antiviral and antitumoral agents nowadays used in therapy are characterized by serious side effects, limiting their use in a large number of cases which on the contrary should take advantage from the therapy; moreover therapeutical progresses are necessary in the clinical treatment of important solid tumors, as for example pulmonary tumors and ovarian tumors, not responding adequately to any treatment nowadays in use.
  • a requisite for the therapeutic progress in this particular field is therefore the discovery of compounds having molecular moieties allowing them to increase the selectivity in inhibiting viral proliferation and the proliferation of tumoral rather than healthy cells.
  • the present invention has the aim to render available new antitumoral and antiviral compounds and in particular compounds
  • the invention refers to pharmaceutical compositions containing the above mentioned compounds , or pharmaceutically acceptable salts thereof formed with inorganic acids such as hydrochloric, hydrobromic, sulfuric, nitric and the like or with organic acids such as acetic, propionic, succinic, malonic, citric, tartaric, ethansulfonic, p-toluensulfonic and the like.
  • inorganic acids such as hydrochloric, hydrobromic, sulfuric, nitric and the like
  • organic acids such as acetic, propionic, succinic, malonic, citric, tartaric, ethansulfonic, p-toluensulfonic and the like.
  • n is as above defined m is zero or an integer comprised between 1 and 3>
  • A cyclohexyl, p-phenylene, 1-methylpyrrole, thiophene, thiazole, imidazole, furan, isoxazole, oxazole, triazole, pyridine, pyrrole.
  • B is a simple bond, or when it is a -CO-NH-CH(R )- group or a -NH-
  • R is preferably methyl, isobutyl, sec-butyl, hydroxymethyl , mercaptomethyl , carbamoylmethyl , benzyl, 4- hydroxybenzyl , 5-imidazolylmethyl, 2-carbamoylethyl , 2- methylthioethyl, 1-hydroxyethyl, 3 ⁇ guanidinopropyl , 4-aminobutyl R ⁇ and R 2 represent preferably an ethyl group, 2-hydroxyethyl , 2- chloroethyl , methansulf onylethyl .
  • B is a chemical bond or the -NHCOCH(R )- group, wherein R? is as above defined, and m, A, R ⁇ and R 2 are as above defined, with a compound of formula (VI)
  • DCC diclohexylcarbodiimide
  • EDC l-dimethylaminopropyl
  • hydrochlorate hydroxybenzotriazole or BOP (benzotriazol-1- iloxy(dimethylaminophosphoniumhexafluoride phosphate) or by using a reactive derivative of the acids (III) and (IV) as for example an acylchloride , an acylimidazole , an acylazide or an active ester, such as 2, 4 , 5 trichlorophenoxyester or N-oxysuccinimidoester, or an anhydride thereof .
  • condensing agents as DCC (dicyclohexylcarbodiimide) or EDC [l-dimethylaminopropyl) -3 ⁇ ethylcarbodiimide hydrochlorate]
  • BOP benzotriazol-1- iloxy(dimethylaminophosphoniumhexafluoride phosphat
  • amidation reactions are carried out using molar ratio of from 1 : 1 to 1 :3 in an inert organic solvent as for example dimethyl sulf oxide , hexamethyl phosphotriamide , dimethylacetamide , or preferably dimethyl formamide in the presence of a condensing agent as above described and of N- hydroxybenzotriazole or BOP and in the presence of an organic base as triethylamine , diisopropylethylamine and l , 8-bis (dimethylamino) - naphthalene.
  • an inert organic solvent as for example dimethyl sulf oxide , hexamethyl phosphotriamide , dimethylacetamide , or preferably dimethyl formamide in the presence of a condensing agent as above described and of N- hydroxybenzotriazole or BOP and in the presence of an organic base as triethylamine , diisopropylethylamine and l , 8-bis
  • the reaction temperature may be comprised between -10 C and 50 C and the time required for the reaction ranges from 2 to 48 hours .
  • the reaction of the compound of formula ( III) or the compound of formula (VII) with the compound, of formula ( IV) may be carried out using a reactive derivative of the compound of formula ( III) or of the compound of formula (VII ) of the above mentioned type , and therefore accomplishing the reaction in a biphasic system water- organic solvent as Schotten-Baumann amidation or in an organic solvent as for example a hydroxyde, a carbonate or a bicarbonate of an alkaline metal , preferably sodium , potassium , barium or an organic base as triethylamine, diisopropylamine , pyridine or N,N dimethylaminopyridine .
  • a compound of formula ( IX) wherein A, m, R ⁇ , R R and Re are as above defined can be prepared by reacting a compound of formula (VIII) wherein A, m, R 1 and R 2 are as above defined or its reactive derivative with a compound of formula (X)
  • a reactive compound of an acid of formula (VIII) can be the same already reported in the present application for the compound of formula (III) or for the compound of formula (VII) and the reaction can be accomplished under similar conditions to those reported for the amidation reaction of a compound of formula (III) or a compound of formula (VII) with a compound of formula (IV).
  • the compounds of formula (X) either are commercially available or can be prepared by the conventional processes starting from the corresponding aminoacids as described for example in E. Gross, J. Meienhofer, The Peptides V. 3, p. 102-132, 198I, Academic Press.
  • A, R ⁇ and R are as above defined, namely compounds of formula (XI)
  • a compound having formula (XII) wherein A, m, R- R 2 , R and Rg are as above defined can be prepared by reacting a compound of formula
  • a reactive derivative of an acid of formula (XIII) can be the same as reported in this application for the compound having formula (III) or for the compound having formula (VII) and the reaction can be carried out under similar conditions to those reported for the amidation reaction of a compound of formula (III) or a compound of formula (VII) with a compound of formula (IV).
  • a compound of formula (IV) either is a commercially available compound or can be prepared by the known methods [Gazzetta Chimica Italiana, 99, 632 (1969)].
  • a compound of formula (VI) can be prepared according to the methods described in the International Patent application No. WO 93/13739 published on 22nd July 1993 in the name of the same applicant and herein reported by reference.
  • the compounds of the present invention have antitumoral and antiviral activity, in particular they show high cytotoxicity levels against the tumoral cellular lines.
  • the present invention relates to pharmaceutical compositions comprising as active principle a compound of general formula (I) or a pharmaceutically acceptable salt thereof with a pharmaceutically acceptable vehicle or diluent.
  • a therapeutically effective amount of the compound of formula (I) according to the invention is combined with an inert and pharmaceutically acceptable vehicle.
  • Conventional vehicles can be used and the compositions can be prepared using the conventional techniques.
  • the compounds according to the present invention are useful for human and animal therapeutical treatment.
  • the compounds according to the present invention are useful as antitumoral and / or antiviral agents when administered to patients in a therapeutically effective amount, for example a suitable dosage for the administation to adult patients can vary from about 0.1 and 100 mg per unitary dose from one to 4 times a day.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Described are pyrrol-amidinic compounds of general formula (I) and their pharmaceutically acceptable salts, processes for their preparation and pharmaceutical compositions containing them, useful as antitumoral.

Description

NOVEL DISTAMYCIN ANALOGUES
Field of the invention The present invention refers to pyrrol-amidinic compounds of general formula (I)
(I) and their pharmaceutically acceptable salts wherein : n is 0 or an integer ranging from 1 to 4 is 0 or an integer ranging from 1 to 4 A is selected from the group consisting of : acyclic, aromatic or heterocyclic residue
B is selected from the group consisting of : a simple chemical bond, -C0-NH-CH(R3)-, -NH-C0-CH(R3)- wherein R^ is H or the side chain of a natural alpha-aminocarboxylic acid; X is selected from the group consisting of : -NHC0-, -C0NH- and wherein : i) R^ and R2 are equal and are selected from the group consisting of : oxiranomethyl, 1-aziridinomethyl, C _/j alkyl optionally substituted in position 2 with an OH, C2_4 alkoxy, halogen or -0S02 ij group wherein R/j is selected from the group consisting of C^_ alkyl or phenyl or ii) R^ = H and R2 is as above described provided that : when B = chemical bond, n is different from 1 when X = -C0NH-, B = simple chemical bond and m = 0, n is different from 0 when B = -C0-NH-CH(R3)- X is different from -NHC0- when B = -NH-C0-CH(R3)- X is different from -C0NH- Furthermore the invention relates to processes for the preparation of the above mentioned compounds, to their pharmacologically active salts and to pharmaceutical compositions containing them.
Prior art
Antibiotic dystamicine is a known compound of formula (II) :
belonging to the pyrrol-amidinic group and showing interesting antiviral activity, for example against the herpetic viruses and Moloney sarcoma virus, is characterized by the ability to interact reversibly and selectively with DNA sequences rich in dA and dT bases thereby interfering both in the replication and transcription process [see Arcamone in B. Pullman and J. Jorterez (eds) "Molecular basis of specificity in nucleic acid - drug interaction" 369-383, 1990 Kluwer Academic Publishers]. As is known, antiviral and antitumoral agents nowadays used in therapy are characterized by serious side effects, limiting their use in a large number of cases which on the contrary should take advantage from the therapy; moreover therapeutical progresses are necessary in the clinical treatment of important solid tumors, as for example pulmonary tumors and ovarian tumors, not responding adequately to any treatment nowadays in use.
A requisite for the therapeutic progress in this particular field is therefore the discovery of compounds having molecular moieties allowing them to increase the selectivity in inhibiting viral proliferation and the proliferation of tumoral rather than healthy cells.
Detailed description of the invention
The present invention has the aim to render available new antitumoral and antiviral compounds and in particular compounds
• analogous to dystamicine containing new chemical modifications at the N- terminal side chain level, and/or containing a different number of pyrrolic residues if compared to the natural product. These compounds, show a marked antitumoral and antiviral activity, as well selectivity in the inhibition of tumoral cells and viruses with respect to the healthy cells.
The compounds according to the present invention are those of general formula (I)
(I) wherein : n, m. A, B, X, R^, R2 are as previously described, and their pharmaceutically acceptable salts.
Besides, the invention, refers to pharmaceutical compositions containing the above mentioned compounds , or pharmaceutically acceptable salts thereof formed with inorganic acids such as hydrochloric, hydrobromic, sulfuric, nitric and the like or with organic acids such as acetic, propionic, succinic, malonic, citric, tartaric, ethansulfonic, p-toluensulfonic and the like. According to the present invention, preferred are the compounds of formula (I) wherein: n is as above defined m is zero or an integer comprised between 1 and 3> A = cyclohexyl, p-phenylene, 1-methylpyrrole, thiophene, thiazole, imidazole, furan, isoxazole, oxazole, triazole, pyridine, pyrrole.
B is a simple bond, or when it is a -CO-NH-CH(R )- group or a -NH-
C0-CH(R3)- group, R is preferably methyl, isobutyl, sec-butyl, hydroxymethyl , mercaptomethyl , carbamoylmethyl , benzyl, 4- hydroxybenzyl , 5-imidazolylmethyl, 2-carbamoylethyl , 2- methylthioethyl, 1-hydroxyethyl, 3~guanidinopropyl , 4-aminobutyl R^ and R2 represent preferably an ethyl group, 2-hydroxyethyl , 2- chloroethyl , methansulf onylethyl .
The following compounds are particularly preferred: 3-[l-Methyl-4-[l-methyl-4-[4-[N,N-bis(2-chloroethyl)amino]benzene- aminocarbonyl]pyrrol-2-carboxyamido]pyrrol-2- carboxyamido ]propionamidine hydrochlorate ;
3-[l-Methyl-4-[l-methyl-4-[l-methyl-4-[l-methyl-4-[4-[N,N-bis(2- chloroethyl) amino]benzeneaminocarbonyl]-pyrrol-2-carboxyamido] pyrrol-2-carboxyamido]pyrrol-2-carboxyamido]pyrrol-2-carboxyamido] propionamidine hydrochlorate ;
3-[l-Methyl-i*-[l-methyl-4-[l-methyl-4-[l-methyl-4-[l-methyl-4-[4-
[N,N-bis(2-chloroethyl)amino]benzeneaminocarbonyl]pyrrol-2- carboxyamido]pyrrol-2-carboxyamido]pyrrol-2-carboxyamido]pyrrol-2- carboxyamido] pyrrol-2-carboxyamido]propionamidine hydrochlorate; 3-[ l-Methyl-4-[l-methyl-4-[4-[N ,N-bis (2-chloroethyl ) amino]benzene butanamido]pyrrol-2-carboxyamido]pyrrol-2-carboxyamido]propiona- midine hydrochlorate ;
3-[l-Methyl-4-[ l-methyl-4-[ l-methyl-4-[l-methyl-4-[4-[N,N-bis (2- chloroethyl ) -amino]benzenbutanamido]pyrrol-2-carboxyamido]pyrrol-2- carboxyamido]pyrrol-2-carboxyamido]pyrrol-2- carboxyamido]propionamidine hydrochlorate ;
3-[ l-Methyl-4-[ l-methyl-4-[l-methyl-4-[ l-methyl-4-[ l-methyl-4-[N,N- bis(2-chloroethyl)amino]benzenebutanamido]pyrrol-2-carboxyamido] pyrrol-2-carboxyamido]pyrrol-2-carboxyamido] pyrrol-2-carboxyamido] pyrrol-2-carboxyamido]propionamidine hydrochlorate;
3-[l-Methyl-4-[l-methyl-4-[4[N,N-bis(2-chloroethyl)amino]benzyl- amino carbonyl]pyrrol-2-carboxyamido]pyrrol-2- carboxyamido]propionamidine hydrochlorate; 3-[l-Methyl-4-[l-methyl-4-[l-methyl-4-[l-methyl-4-[4-[N,N-bis(2 chloroethylamino)benzylaminocarbonyl]pyrrol-2-carboxyamido]pyrrol-2- carboxyamido]pyrrol-2-carboxyamido]pyrrol-2-carboxyamido]propiona- midine hydrochlorate;
3-[l-Methyl-4-[l-methyl-4-[2-[4-[N,N-bis(2-chloroethyl)amino) phenyl] ethanaminocarbonyl]pyrrol-2-carboxyamido]pyrrol-2-carboxa- mido] propionamidine hydrochlorate;
3-[l-Methyl-4-[l-methyl-4-[l-methyl-4-[l-methyl-4-[2-[4-[N,N-bis
(2-chloroethyl ) amino]phenyl]ethanaminocarbonyl]pyrrol-2-carboxa- mido]pyrrol -2- carboxyamido ]pyrrol-2-carboxyamido]pyrrol-2- carboxyamido ]propionamidine hydrochlorate ;
3-[ l-Methyl-4-[ l-methyl-4-[3-[4-[N,N-bis (2-chloroethyl ) amino] phenyl]propylaminocarbonyl]pyrrol-2-carboxyamido]pyrrol-2-carboxa- mido] propionamidine hydrochlorate; 3-[l-Methyl-4-[l-methyl-4-[l-methyl-4-[l-methyl-4-[3-[4-[N,N-bis(2- chloroethyl)amino]phenyl]propylaminocarbonyl]pyrrol-2- carboxyamido]pyrrol-2-carboxyamido]pyrrol-2-carboxyamido]pyrrol-2- carboxyamido] propionamidine hydrochlorate;
3-[l-methyl-4-[l-methyl-4-[l-methyl-4-[l-methyl-4-[l-methyl-4-[3- [4-[N,N-bis(2-chloroethyl)amino]phenyl]propylaminocarbonyl]pyrrol-
2-carboxyamido]pyrrol-2-carboxyamido]pyrrol-2-carboxyamido]pyrrol-2- carboxyamido]pyrrol-2-carboxyamido]propionamidine hydrochlorate;
3-[l-Methyl-4-[l-methyl-4-[4-[N,N-bis(2-chloroethyl)amino]benzyl carboxyamido]pyrrol-2-carboxyamido]pyrrol-2- carboxyamido]propionamidine hydrochlorate;
3-[l-Methyl-4-[l-methyl-4-[l-methyl-4-[l-methyl-4-[4-[N,N-bis(2- chloroethyl)amino]benzylcarboxyamido]pyrrol-2-carboxyamido]pyrrol-
2-carboxyamido]pyrrol-2-carboxyamido]pyrrol-2-carboxyamido] propionamidine hydrochlorate; 3-[l-Methyl-4-[l-methyl-4-[2-[4-[N,N-bis(2-chloroethyl)amino] phenyl]ethylcarboxyamido]pyrrol-2-carboxyamido]pyrrol-2-carboxy- amido]propionamidine hydrochlorate;
3-[l-Methyl-4-[l-methyl-4-[l-methyl-4-[l-methyl-4-[2-[4-[N,N-bis
(2-chloroethyl)amino]phenyl]ethylcarboxyamido]pyrrol-2- carboxyamido]pyrrol-2-carboxyamido]pyrrol-2-carboxyamido]pyrrol-2- carboxyamido]propionamidine hydrochlorate;
3-[l-Methyl-4-[l-methyl-4-[l-methyl-4-[N,a-[4-[N,N-bis(2-chloro- ethyl)amino]benzoyl]glycylamino]pyrrol-2-carboxyamido]pyrrol-2- carboxyamido]pyrrol-2-carboxyamido]propionamidine hydrochlorate; 3-[l-Methyl-4-[l-methyl-4-[l-methyl-4-[l-methyl-4-[N,a-[4-[N,N- bis(2-chloroethyl)amino]benzoyl]glycylamino]-pyrrol-2- carboxyamido]pyrrol-2-carboxyamido]pyrrol-2-carboxyamido]pyrrol-2- carboxyamido]propionamidine hydrochlorate;
Compounds of general formula (I) can be prepared according to the following processes: a) reacting the compound of formula (III)
Λ
N-A-(CH2)m-B-C00H
/
R-
(III) wherein B is a chemical bond or the -CONHCH(R )- group wherein R-, is as above defined, and m, A, R< and R are as above defined, or a reactive derivative thereof, with a compound of formula (IV)
:ιv) wherein p is an integer comprised between 2 and 6 , thereby obtaining the compounds of formula ( I ) wherein X = -C0NH- , B is a chemical bond or the -CO-NH-CH(Ro ) - group and m, n. A, B, Rj , R2 and R are as above defined; a1 ) reacting the compound of formula (V)
(V)
wherein B is a chemical bond or the -NHCOCH(R )- group, wherein R? is as above defined, and m, A, R^ and R2 are as above defined, with a compound of formula (VI)
H
(VI) wherein p is an integer comprised between 2 and 6, thereby obtaining the compounds of formula (I) wherein X = -NHC0-, B is a chemical bond or the -NH-CO-CH(Ro)- group and m, n, A, B, R- R2 and R-, are as above defined; b) reacting the compound of formula (VII)
wherein m. A, X, R and R are as above defined, with a compound of formula (IV)
(IV) wherein p is an integer comprised between 1 and 5. thereby obtaining the compounds of formula (I) wherein B is a chemical bond and m, n, A, X, R^ and R2 are as above defined.
The amidation reactions of the compound of formula (III) with a compound of formula (IV) wherein p is an integer comprised between 2 and 6, of the compound of formula (V), wherein R^, R , A, m and B are as previously defined, with the compound of formula (VI) , wherein p is comprised between 2 and 6, and of the compound of formula (VII), wherein R^, R , A, m, X are as above defined, with a compound of formula (IV) wherein p is an integer comprised between 1 and 5. can be carried out in the presence of condensing agents as DCC (dicyclohexylcarbodiimide) or EDC [l-dimethylaminopropyl) -3~ ethylcarbodiimide hydrochlorate] and possibly in the presence of hydroxybenzotriazole or BOP (benzotriazol-1- iloxy(dimethylaminophosphoniumhexafluoride phosphate) or by using a reactive derivative of the acids (III) and (IV) as for example an acylchloride , an acylimidazole , an acylazide or an active ester, such as 2, 4 , 5 trichlorophenoxyester or N-oxysuccinimidoester, or an anhydride thereof . Preferably the above defined amidation reactions are carried out using molar ratio of from 1 : 1 to 1 :3 in an inert organic solvent as for example dimethyl sulf oxide , hexamethyl phosphotriamide , dimethylacetamide , or preferably dimethyl formamide in the presence of a condensing agent as above described and of N- hydroxybenzotriazole or BOP and in the presence of an organic base as triethylamine , diisopropylethylamine and l , 8-bis (dimethylamino) - naphthalene.
The reaction temperature may be comprised between -10 C and 50 C and the time required for the reaction ranges from 2 to 48 hours . The reaction of the compound of formula ( III) or the compound of formula (VII) with the compound, of formula ( IV) may be carried out using a reactive derivative of the compound of formula ( III) or of the compound of formula (VII ) of the above mentioned type , and therefore accomplishing the reaction in a biphasic system water- organic solvent as Schotten-Baumann amidation or in an organic solvent as for example a hydroxyde, a carbonate or a bicarbonate of an alkaline metal , preferably sodium , potassium , barium or an organic base as triethylamine, diisopropylamine , pyridine or N,N dimethylaminopyridine . The reaction is usually conducted at room temperature and the time required for the reaction varies from 2 to 24 hours . In the process (a) , the compounds of formula (III) wherein B is a chemical bond and m , A , R and R2 are as above defined , namely the compounds of formula (VIII)
Rl
\
N-A- (CH2) -C00H
/ R2
(VIII)
either are already commercially available or they are prepared by conventional processes of the organic chemistry, starting from known compounds as reported for example in J. Med. Chem. 32, 774 (1989) or J. Org. Chem. 26, 4996 or in J. Med. Chem. 33, 1177 (1990). In the process (a) a compound of formula (III) wherein B is the group -CO-NH-CH(R )- and m. A, R^, R2 and R-> are as above defined, can be prepared by the hydrolysis of the compounds of formula (IX)
Rl.
\
N-A-(CH2)m-C0-NH-CH(R,)-C00R5
R2
(IX) wherein A , m , Rj_ , R2 , R-a are as above defined and Rr is a protecting group characteris tic of the carboxylic group of aminoacids as methyl , ethyl , t-butyl , benzyl , trimethylsilyl , the hydrolysis of the compound of formula ( IX ) can be carried out following the known methods and processes of the organic chemistry as for example reported in T. W . Greene Protective groups in Organic Synthesis Wiley Interscience Publication 198l . A compound of formula ( IX) wherein A, m, R^ , R R and Re are as above defined, can be prepared by reacting a compound of formula (VIII) wherein A, m, R1 and R2 are as above defined or its reactive derivative with a compound of formula (X)
H2N-CH(R3) -C00R5
(X) wherein R-, and Re have the above defined meanings. A reactive compound of an acid of formula (VIII) can be the same already reported in the present application for the compound of formula (III) or for the compound of formula (VII) and the reaction can be accomplished under similar conditions to those reported for the amidation reaction of a compound of formula (III) or a compound of formula (VII) with a compound of formula (IV). The compounds of formula (X) either are commercially available or can be prepared by the conventional processes starting from the corresponding aminoacids as described for example in E. Gross, J. Meienhofer, The Peptides V. 3, p. 102-132, 198I, Academic Press. In the process (a1) a compound of formula (V) wherein B is a chemical bond and m. A, R^ and R are as above defined, namely compounds of formula (XI)
\
N-A-(CH2)m-NH2
/ R2
(XI) either are commercially available or are prepared by the conventional processes of the organic chemistry as reported for example in J. Med. Chem. 33. 112 (1990).
In the process (a') a compound of formula (V) wherein B is the group -NHCOCH(R ) wherein m. A, Rj_, R2 and R are as above defined, can be prepared by hydrolysis of the compounds of formula (XII)
Rl.
\
N-A-(CH2)m-NH-C0-CH(R^)-NHRg
R2
(XII) wherein A, m, R , R2, R are as above defined and Rg is a protecting group characteristic of the amino group of aminoacids as trifluoroacetyl, benzyloxycarbonyl, tertbutyloxycarbonyl, 9~ fluorenylmethyloxycarbonyl and trityl, the hydrolysis of the compound of formula (XII) can be carried out following the methods and processes known in the organic chemistry as for example reported in T. W. Greene Protective group in Organic Synthesis Wiley Interscience Publication 1981.
A compound having formula (XII) wherein A, m, R- R2, R and Rg are as above defined can be prepared by reacting a compound of formula
(XI) wherein A, m, R^ and R2 are as above defined, with a compound of formula (XIII)
HOOC-CH(R3)-NHR6
(XIII) wherein R-, and R are as above defined, or with its reactive derivative.
A reactive derivative of an acid of formula (XIII) can be the same as reported in this application for the compound having formula (III) or for the compound having formula (VII) and the reaction can be carried out under similar conditions to those reported for the amidation reaction of a compound of formula (III) or a compound of formula (VII) with a compound of formula (IV).
The compounds of formula (XIII) either are commercially available or are prepared by conventional procedures, starting from aminoacids as described for example in E. Gross, J. Meienhofer, The
Peptides V. 3. P- 102-132, 1981, Academic Press.
In the process (b) , a compound of formula (VII) wherein . A, X, R^ and R are as above defined, can be prepared as described in the International Patent application No. WO 93/13739 published on 22nd
July 1993 in the name of the same applicant and herein reported by reference. In the processes (a) and (b) a compound of formula (IV) either is a commercially available compound or can be prepared by the known methods [Gazzetta Chimica Italiana, 99, 632 (1969)]. In the process (a') a compound of formula (VI) can be prepared according to the methods described in the International Patent application No. WO 93/13739 published on 22nd July 1993 in the name of the same applicant and herein reported by reference. The compounds of the present invention have antitumoral and antiviral activity, in particular they show high cytotoxicity levels against the tumoral cellular lines.
Moreover the present invention relates to pharmaceutical compositions comprising as active principle a compound of general formula (I) or a pharmaceutically acceptable salt thereof with a pharmaceutically acceptable vehicle or diluent. A therapeutically effective amount of the compound of formula (I) according to the invention is combined with an inert and pharmaceutically acceptable vehicle. Conventional vehicles can be used and the compositions can be prepared using the conventional techniques. The compounds according to the present invention are useful for human and animal therapeutical treatment.
In particular, the compounds according to the present invention are useful as antitumoral and / or antiviral agents when administered to patients in a therapeutically effective amount, for example a suitable dosage for the administation to adult patients can vary from about 0.1 and 100 mg per unitary dose from one to 4 times a day.
EXAMPLE 1
3-[l-Methyl-4-[l-methyl-4-[l-methyl-4-[l-methyl-4-[4-[N ,N-bis (2- chloroethyl ) amino]benzenbutanamido]pyrrol-2-carboxyamido]pyrrol-2- carboxyamido]pyrrol-2-carboxyamido]pyrrol-2-carboxyamido]propiona- midine hydrochlorate
(I, X = -C0NH- , A = p-phenylene, B = 0 m = 3. n = 2, 1 = R2 = 2- chloroethyl ) . 4-[Bis (2-chloroethyl) amino]benzenebutanoylchloride (801 mg, 2.49 mmoles ) , (obtained by the corresponding carboxylic acid VIII, (A = p-phenylene , m = 3 , R^ = R2 = 2-chloroethyl) (750 mg, 2.49 mmoles) by treatment with S0C12 (1.2 ml) in tetrahydrofuran (25 ml) under reflux) , are dissolved in 2 ml anhydrous tetrahydrofuran and added to a solution of 3-[l-Methyl-4-[l-methyl-4-[l-methyl-4- ( l-methyl-4- aminopyrrole-2-carboxyamido)pyrrol-2-carboxyamido]pyrrol-2- carboxyamido ] pyrrol -2- carboxyamido ] propionamidine hydrochlorate
(IV, p = 4) ( 327 mg, 0.51 mmoles) , [Gazzetta Chimica Italiana, 99. 632 ( 1969 ) ] and sodium bicarbonate (90 mg, 1 .11 mmoles) in 40 ml water. After one hour stirring at room temperature , the reaction mixture is evaporated to dryness and the residue is separated by chromatography on silica gel (eluent CHCl^/MeOH 7/3) thus obtaining 276 mg I (X = -C0NH- , A = p-phenylene , B = 0 , m = 3 , n = 2 , R: = R2 = 2-chloroethyl ) (yield 60 % ) . ^-NMR (DMSO-d6), d : 1.82 (m, 2H) , 2.25 (t, 2H) , 2.45 (t. 2H), 2.64 (t, 2H). 3.50 (m, 2H) , 3-70 (s. 8H) , 3-82 (s, 3H), 3.85 (s. 3H), 3-86 (s, 3H) , 3-87 (s, 3H) , 6.69 (d, 2H). 6.90 (d, 1H), 6.97 ( , 1H) , 7-04 (d, 2H) , 7-08 (bs, 2H), 7.15 (d, 1H), 7.18 (d, 1H) , 7-22 (bs, 2H) , 8.19 (t, 1H), 8.57 (bs,2H), 8.95 (bs, 2H) , 9-76 (s.lH). 9-90 (m,3H).
The following compound of formula (I) is also obtained by an analogous process: 3-[l-Methyl-4-[l-methyl-4-[4-[N,N-bis(2-chloroethyl)amino]benzene butanamido]pyrrol-2-carboxyamido]pyrrol-2-carboxyamido] propiona¬ midine hydrochlorate (I, X = -C0NH-, A = p-phenylene, B = 0, m = 3. n = 0, R = R2 = 2-chloroethyl) . XH-NMR (DMS0-d6), d : 1.80 (m, 2H) , 2.24 (t, 2H) , 2.50 (t, 2H). 2.62 (t. 2H). 3-50 (m, 2H) , 3-70 (s, 8H) . 3-8l (s. 3H), 3-83 (s, 3H). 6.68 (d, 2H) , 6.87 (d, 1H) , 6.92 (d. 1H). 7.04 (d, 2H). 7.13 (d, 1H), 7.16 (d. 1H), 8.18 (t, 1H), 8.65 (bs. 2H). 8.94 (bs, 2H) . 9-75 (s. 1H). 9-83 (s, 1H). EXAMPLE 2
3-[l-Methyl-4-[l-methyl-4-[l-methyl-4-[l-methyl-4-[4-[N,N-bis(2- chloroethyl)amino]benzenaminocarbonyl]pyrrol-2-carboxyamido]pyrrol- 2-carboxyamido]pyrrol-2-carboxyamido]pyrrol-2-carboxyamido] propio¬ namidine hydrochlorate (I, X = -NHC0-, A = p-phenylene, B = 0, m = 0, n = 2, R1 = R2 = 2- chloroethyl) .
(337 mg, 0.84 mmoles) of l-Methyl-4-[4-[N,N-bis(2-chloroethyl)- amino]benzenaminocarbonyl] pyrrol-2-carboxylic acid chloride (VII, A = p-phenylene, X = -NHC0-, m = 0, R = 2 = 2-chloroethyl) , (obtained by treatment of the carboxylic acid VII (A = p-phenylene, X = -NHC0-, m = 0, = R2 = 2-chloroethyl) (322 mg, 0.84 mmoles) with S0C12 (4.2 mmoles) dissolved in CH2C1 and in the presence of dimethylformamide) , are dissolved in 10 ml tetrahydrofuran and added to a mixture of N-deformyldystamicine (221 mg, 0.42 mmoles) and diisopropylethylamine (0.3 ml, 2.1 mmoles) in anhydrous EtOH (5 ml).
The mixture is maintained 30 minutes under stirring at room temperature, then ethylacetate is added up to the precipitation of the raw product, which after separation by HPLC (H20/CH CN/CF C00H 56/44/0.1) gives 162 mg of I (X = -NHC0-, A = p-phenylene, B = 0, m = 0, n = 2, Rχ = R2 = 2-chloroethyl), (yield 45 %) . ^-NMR (DMS0-d6), d : 2.60 (t, 2H) , 3-50 (m, 2H) , 3-70 (s. 8H), 3.81 (s, 3H). 3-86 (s, 3H) , 3-88 (s, 3H). 3-92 (s, 3H), 6.74 (d, 2H), 6.96 (d, 1H) , 7.08 (s, 2H) , 7-18 (d. 2H), 7.25 (d, 1H). 7-28 (d, 1H) , 7-42 (d, 1H) , 7-54 (d, 2H), 7.69 (d, 1H), 8.17 (t, 1H) , 8.50 (bs, 2H) , 8.59 (bs, 2H), 9.49 (s, 1H), 9.88 (s, 1H) , 9-94 (s, 1H) , 10.09 (s, 1H). The following compound of formula (I) is also obtained by an analogous process:
3-[l-Methyl-4-[l-methyl-4-[l-methyl-4-[l-methyl-4-[l-methyl-4-[4- [N,N-bis(2-chloroethyl)amino]benzenaminocarbonyl]pyrrol-2- carboxyamido]pyrrol-2-carboxyamido]pyrrol-2-carboxyamido]pyrrol-2- carboxyamido]pyrrol-2-carboxyamido] propionamidine hydrochlorate (I, X = -NHC0-, A = p-phenylene, B = 0, m = 0, n = 3, Rχ = R2 = 2- chloroethyl) .
1H-NMR (DMS0-d6), d : 2.60 (t, 2H) , 3.50 (m, 2H) , 3.70
(s. 8H), 3.81 (s. 3H). 3.85 (s, 3H), 3.87 (s. 6H), 3.92 (s. 3H). 6.72 (d, 2H), 6.95 (d, 1H). 7-07 (m, 3H) . 7-16
(d, 1H), 7.21 (d, 1H), 7.23 (d, 1H). 7-26 (d, 1H), 7-4l(d. 1H), 7.52 (d, 2H). 7-68 (d, 1H), 8.18 (t, 1H) , 8.47 (bs, 2H). 8.89 (bs, 2H), 9.48 (s. 1H) , 9-88 (s, 1H) 9-90 (s. 1H), 9.93 (s. 1H), 10.09 (s. 1H) EXAMPLE 3
N-[4-[N,N-bis(2-chloroethyl)amino]benzoyl]glycine (III, A = p- phenylene, m = 0, 1 = R2 = 2-chloroethyl, B = -C0NHCH(R3)-, R =
H)
A mixture composed by glycine ( 600 mg, 8 mmoles), bis( trimethylsilyl)acetamide (3-25 g, 1 mmoles), and trimethylsilylchloride (0.2 ml, 1.6 mmoles) in CH C12 (20 ml) is kept under reflux for 2 hours.
After cooling to room temperature, (3 g, 10.8 mmoles) of 4-[N,N- bis (2-chloroethyl)amino]benzoylchloride are added to the reaction mixture, which is maintained under stirring at 40 C. After 2 hours, the mixture is acidified with IN HCl and extracted with CH2C12; the organic extracts are collected and extracted on their turn with an aqueous solution of NaHCO , and the basic phase, after acidification with IN HCl is extracted with CH2C12 thus obtaining after evaporation of the organic phase, 1.32 g of III (A = p-phenylene. m = 0, Rχ = R2 = 2-chloroethyl, B - -C0NHCH(R3)-, R3 = H), (yield 52 % ) :H-NMR (DMS0-d6), d : 3-78 (m, 8H) , 3-88 (d, 2H) , 6.78 (d, 2H). 7-72 (d, 2H), 8.46 (t, 1H).
EXAMPLE 4 3-[l-Methyl-4-[l-methyl-4-[l-methyl-4-[N,a-[4-[N,N-bis(2- chloroethyl ) amino]benzoyl ]glycylamino]pyrrol-2-carboxyamido]pyrrol- 2-carboxyamido]pyrrol-2-carboxyamido]propionamidine hydrochlorate (I, X = -C0NH- , A = p-phenylene, B = -C0NHCH(R3) - , R3 = H, m = 0, n = 1 , R1 = R2 = 2-chloroethyl) .
308 mg (O.58 mmoles) N-deformyldystamicine, 136 mg ( 1 mmole) N- hydroxybenzotriazole (HOBT) , 182 mg ( 0.85 ) mmoles 1 .8-bis- (dimethylamino ) -naphthalene and 191 mg ( 0. 11 mmoles ) [ l- ( 3~ dimethylaminopropyl ) -3-ethylcarbodiimide ( EDC ) are added to a solution of 270 mg, (O.85 mmoles) III (A = p-phenylene, m = 0, R^ = R2 = 2-chloroethyl , B = -C0NHCH ( R ) - , R = H ) , prepared as described in example 3 and dissolved in anhydrous dimethylformamide (45 ml) . The reaction mixture is maintained under stirring at room temperature for one hour, then ethylacetate is added up to precipitation of the raw product, which after chromatography on silica gel (eluent CH2Cl2/anhydrous Et0H/H20 65/35/2) gives 275 mg of I (X = -C0NH-, A = p-phenylene, B * -C0NHCH(R3)-, R3 = H, = 0, n = 1, R1 = R2 = 2-chloroethyl) (yield 60 %)
^-NMR (DMS0-d6), d : 2.64 (t, 2H) , 3-50 (m, 2H) . 3-78 (s, 8H), 3.82 (s, 3H), 3-84 (s, 6H) , 3-97 (d. 2H), 6.78 (d, 2H), 6.91 (s, 2H), 7.04 (d, 1H). 7.14 (d, 1H) . 7-18 (d, 1H), 7.21 (d. 1H). 7-78 (d, 2H), 8.21 (t, 1H) , 8.52 (t, 1H), 8.78 (bs, 2H), 9-04 (bs, 2H) , 9-89 (s, 2H) , 9-95 (s, 1H).

Claims

CLAIMS 1. Compounds of general formula (I)
(I) and their pharmaceutically acceptable salts wherein : n is 0 or an integer ranging from 1 to 4 m is 0 or an integer ranging from 1 to 4 A is selected from a group consisting of : an acyclic, aromatic or heterocyclic residue B is selected from the group consisting of : simple chemical bond, -C0-NH-CH(R3)-, -NH-C0-CH(R )- wherein R is H or the side chain of a natural alpha-carboxylic acid X is selected from the group consisting of : -NHC0-, -C0NH- and wherein : i) Ri and R2 are equal and are selected from the group consisting of: oxiranomethyl, 1-aziridinomethyl, ^2-k alkyl optionally substituted in position 2 with a -OH, ^2- a koχy« halogen or -0S02Rh group wherein R^ is selected from the group consisting of C^ alkyl or phenyl or ii) R^ = H and R2 is as above described provided that : when B = chemical bond, n is different from 1 when X = -C0NH-, B = simple chemical bond and m = 0 n is different from 0 when B = -C0-NH-CH(R3)- X is different from -NHC0- when B = -NH-C0-CH(R3)- X is different from -C0NH- 2. The compounds as claimed in claim 1 wherein: n is as above defined m is zero or an integer comprised between 1 and 3> A = cyclohexyl, p-phenylene, 1-methylpyrrole, thiophene, thiazole, imidazole, furan, isoxazole, oxazole, triazole, pyridine, pyrrole. B is a simple chemical bond, or when it is a -CO-NH-CH(Ro)- group or a -NH-C0-CH(R3)- group, R-, is preferably methyl, isobuthyl, sec- buthyl, hydroxymethyl, mercaptomethyl, carbamoylmethyl, benzyl, 4- hydroxybenzyl, 5-imidazolylmethyl, 2-carbamoylethyl, 2- methylthioethyl, 1-hydroxyethyl, 3-guanidinopropyl, 4-aminobutyl R^ and R2 represent preferably an ethyl group, 2-hydroxyethyl, 2- chloroethyl, methansulfonylethyl. 3- The compounds of formula (I) as claimed in claim 2. selected from the group consisting of: 3"[l~-'ethyl-4-[l-methyl-4-[4-[N,N-bis(2-chloroethyl)amino]benzene- aminocarbonyl]pyrrol-2-carboxyamido]pyrrol-2-carboxyamido]propiona- midine hydrochlorate ; 3-[l-Methyl-4-[l-methyl-4-[l-methyl-4-[l-methyl-4-[4-[N,N-bis (2- chloroethyl) amino]benzeneaminocarbonyl]-pyrrol-2-carboxyamido] pyrrol-2-carboxyamido]pyrrol-2-carboxyamido]pyrrol-2-carboxyamido] propionamidine hydrochlorate; 3-[l-Methyl-4-[l-methyl-4-[l-methyl-4-[l-methyl-4-[l-methyl-4-[4- [N,N-bis(2-chloroethyl)amino]benzeneaminocarbonyl]pyrrol-2- carboxyamido]pyrrol-2-carboxyamido]pyrrol-2-carboxyamido]pyrrol-2- carboxyamido] pyrrol-2-carboxyamido]propionamidine hydrochlorate; 3-[l-Methyl-4-[l-methyl-4-[4-[N,N-bis(2-chloroethyl)amino]benzene butanamido]pyrrol-2-carboxyamido]pyrrol-2-carboxyamido]propiona- midine hydrochlorate; 3-[l-Methyl-4-[l-methyl-4-[l-methyl-4-[l-methyl-4-[4-[N,N-bis(2- chloroethyl)-amino]benzenebutanamido]pyrrol-2-carboxyamido]pyrrol- 2-carboxyamido]pyrrol-2-carboxyamido]pyrrol-2-carboxyamido] propio- namidine hydrochlorate; 3-[l-Methyl-4-[l-methyl-4-[l-methyl-4-[l-methyl-4-[l-methyl-4-[N,N- bis(2-chloroethyl)amino]benzenebutanamido]pyrrol-2-carboxyamido] pyrrol-2-carboxyamido]pyrrol-2-carboxyamido] pyrrol-2-carboxyamido] pyrrol-2-carboxyamido]propionamidine hydrochlorate; 3-[l-Methyl-4-[l-methyl-4-[4[N,N-bis(2-chloroethyl)amino]benzyl- amino carbonyl]pyrrol-2-carboxyamido]pyrrol-2-carboxyamido]propio- namidine hydrochlorate; 3-[l-Methyl-4-[l-methyl-4-[l-methyl-4-[l-methyl-4-[4-[N,N-bis(2 chloroethylamino)benzylaminocarbonyl]pyrrol-2-carboxyamido]pyrrol-2- carboxyamido]pyrrol-2-carboxyamido]pyrrol-2-carboxyamido]propiona- midine hydrochlorate; 3-[l-Methyl-4-[l-methyl-4-[2-[4-[N,N-bis(2-chloroethyl)amino) phenyl] ethanaminocarbonyl]pyrrol-2-carboxyamido]pyrrol-2-carboxya- mido] propionamidine hydrochlorate; 3-[l-Methyl-4-[l-methyl-4-[l-methyl-4-[l-methyl-4-[2-[4-[N,N-bis (2-chloroethyl ) amino]phenyl]ethanaminocarbonyl]pyrrol-2-carboxya- mido]pyrrol-2-carboxyamido]pyrrol-2-carboxyamido]pyrrol-2- carboxyamido]propionamidine hydrochlorate ; 3-[ l-Methyl-4-[ l-methyl-4-[3-[4-[N, N-bis (2-chloroethyl) amino] phenyl ]propylaminocarbonyl]pyrrol-2-carboxyamido]pyrrol-2-carboxya- mido] propionamidine hydrochlorate; 3-[l-Methyl-4-[l-methyl-4-[l-methyl-4-[l-methyl-4-[3-[4-[N,N-bis(2- chloroethyl)amino]phenyl]propylaminocarbonyl]pyrrol-2- carboxyamido]pyrrol-2-carboxyamido]pyrrol-2-carboxyamido]pyrrol-2- carboxyamido] propionamidine hydrochlorate; 3-[l-methyl-4-[l-methyl-4-[l-methyl-4-[l-methyl-4-[l-methyl-4-[3- [4-[N,N-bis(2-chloroethyl)amino]phenyl]propylaminocarbonyl]pyrrol- 2-carboxyamido]pyrrol-2-carboxyamido]pyrrol-2-carboxyamido]pyrrol-2- carboxyamido]pyrrol-2-carboxyamido]propionamidine hydrochlorate; 3-[l-Methyl-4-[l-methyl-4-[4-[N,N-bis(2-chloroethyl)amino]benzyl carboxyamido] pyrrol -2-carboxyamido]pyrrol-2-carboxyamido]propio- namidine hydrochlorate ; 3-[l-Methyl-4-[l-methyl-4-[l-methyl-4-[l-methyl-4-[4-[N,N-bis(2- chloroethyl)amino]benzylcarboxyamido]pyrrol-2-carboxyamido]pyrrol- 2-carboxyamido]pyrrol-2-carboxyamido]pyrrol-2-carboxyamido] propionamidine hydrochlorate; 3-[l-Methyl-4-[l-methyl-4-[2-[4-[N,N-bis(2-chloroethyl)amino] phenyl]ethylcarboxyamido]pyrrol-2-carboxyamido]pyrrol-2-carboxy- amido]propionamidine hydrochlorate; 3-[l-Methyl-4-[l-methyl-4-[l-methyl-4-[l-methyl-4-[2-[4-[N, -bis (2-chloroethyl)amino]phenyl]ethylcarboxyamido]pyrrol-2- carboxyamido]pyrrol-2-carboxyamido]pyrrol-2-carboxyamido]pyrrol-2- carboxyamido]propionamidine hydrochlorate; 3-[l-Methyl-4-[l-methyl-4-[l-methyl-4-[N,a-[4-[N,N-bis(2-chloro- ethyl ) amino]benzoyl]glycylamino]pyrrol-2-carboxyamido]pyrrol-2- carboxyamido]pyrrol-2-carboxyamido]propionamidine hydrochlorate ; 3-[l-Methyl-4-[ l-methyl-4-[ l-methyl-4-[ l-methyl-4-[N, a-[4-[N ,N- bis (2-chloroethyl) amino ]benzoyl]glycylamino]-pyrrol-2- carboxyamido ]pyrrol-2-carboxyamido]pyrrol-2-carboxyamido]pyrrol-2- carboxyamido ] propionamidine hydrochlorate; 4. Compounds of formula (VI)
HO
(VI ) wherein p is an integer comprised between 3 and 6. 5 - Compounds of formula ( IX)
N-A- ( CH2 ) m-C0-NH-CH ( R3 ) -C00R5
wherein A, m, R^, R , R-, and Re are as claimed in claims 1) and 2) 6. Compounds of formula (XII)
N-A-(CH2)m-NH-C0-CH(R3)-NHRg
wherein A, m, R^, R2, R-> and Rg are as claimed in claims 1) and 2) 7> A process for the preparation of compounds of formula (I)
(I) wherein : n is 0 or an integer ranging from 1 to 4 m is 0 or an integer ranging from 1 to 4 A is selected from the group consisting of : an acyclic, aromatic or heterocyclic residue. B is selected from the group consisting of : simple chemical bond, -C0-NH-CH(R3)-, -NH-C0-CH(R3)- wherein R is H or the side chain of a natural alpha-carboxylic acid X is selected from the group consisting of : -NHC0-, -C0NH- and wherein : i) R^ and R2 are equal and are selected from the group consisting of: oxiranomethyl, 1-aziridinomethyl, ^2- alkyl optionally substituted in position 2 with a OH, C2_4 alkoxy, halogen or -0S0 Rj| group wherein R^ is selected from the group consisting of C1_it alkyl or phenyl or ii) R^ = H and R2 is as above described provided that : when B = chemical bond, n is different from 1 when X = -C0NH-, B = simple chemical bond and m = 0, n is different from 0 when B = -CO-NH-CH(Rn)- X is different from -NHC0- when B = -NH-CO-CH(R )- X is different from -C0NH- comprising reacting the compound of formula (III), wherein A, m, B, Rj and R2 are as above defined, with a compound of formula (IV)
wherein p is an integer comprised between 2 and 6. 8. A process for the preparation of compounds of formula (I)
(I) wherein: B is a simple chemical bond or a -NH-CO-CH(Rτ)- group, X is the -NHC0- group and , n, R^ , R and R-, are as claimed in claim 7), provided that, if B is a chemical bond n is different from 1; comprising reacting the compound of formula (V) \
N-A- (CH2)m-B-NH2 /
R-
(V) wherein A, B, m, R-^ and R are as above defined, with a compound of formula (VI )
(VI) wherein p is an integer comprised between 2 and 6. 9- A process for the preparation of the compounds of formula (I)
(i) wherein : B is a simple chemical bond X represent the -NHCO- group or the -CONH- group and m, n, A, R1 and R2 are defined in claim 7) . provided that: if B is a chemical bond, n is different from 1; if X is -CONH- and contemporaneously B is a chemical bond and m is equal to zero, n is different from zero; comprising reacting the compound of formula (VII)
(VII)
wherein A, X, , R, and R2 are as above defined, with a compound of formula (IV)
(IV) wherein p is an integer comprised between 1 and 5 - 10. Use of compounds as claimed in claims 1-3 for the preparation of pharmaceutical compositions . 11. Pharmaceutical compositions containing as active principle a compound as claimed in claim 1 in combination with a pharmaceutically acceptable vehicle or diluent . 12. The pharmaceutical compositions as claimed in claim 11 as antitumoral agents . 13. The pharmaceutical compositions as claimed in claim 11 as antiviral agents . 14. A therapeutic method for the treatment of tumoral affections comprising administering to patients , from 1 to 4 times a day, pharmaceutical compositions containing as active ingredient a compound as claimed in claim 1 , in an amount ranging from 0.1 to 100 mg per unitary dose in a pharmaceutically acceptable diluent or vehicle . 15. A therapeutic method for the treatment of viral affections comprising administering to patients , from 1 to 4 times a day, pharmaceutical composi tions containing as active ingredient a compound as claimed in claim 1 , in an amount ranging from 0.1 to 100 mg per unitary dose in a pharmaceutically acceptable diluent or vehicle .
EP94909068A 1993-03-01 1994-02-25 Novel distamycin analogues Withdrawn EP0690840A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
ITFI930030 1993-03-01
ITFI930030A IT1271456B (en) 1993-03-01 1993-03-01 PYROL-AMIDINE COMPOUNDS, AND THEIR PHARMACEUTICALLY ACCEPTABLE SALTS, PREPARATION PROCESSES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
PCT/EP1994/000557 WO1994020463A1 (en) 1993-03-01 1994-02-25 Novel distamycin analogues

Publications (1)

Publication Number Publication Date
EP0690840A1 true EP0690840A1 (en) 1996-01-10

Family

ID=11350335

Family Applications (1)

Application Number Title Priority Date Filing Date
EP94909068A Withdrawn EP0690840A1 (en) 1993-03-01 1994-02-25 Novel distamycin analogues

Country Status (7)

Country Link
EP (1) EP0690840A1 (en)
JP (1) JPH08508720A (en)
KR (1) KR960701007A (en)
AU (1) AU6206894A (en)
CA (1) CA2157187A1 (en)
IT (1) IT1271456B (en)
WO (1) WO1994020463A1 (en)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9416005D0 (en) * 1994-08-08 1994-09-28 Erba Carlo Spa Peptidic compounds analogous to distamycin a and process for their preparation
US6555692B1 (en) 1996-02-26 2003-04-29 California Institute Of Technology Preparation and use of bifunctional molecules having DNA sequence binding specificity
AU734715B2 (en) 1996-02-26 2001-06-21 California Institute Of Technology Improved polyamides for binding in the minor groove of double stranded DNA
US6090947A (en) * 1996-02-26 2000-07-18 California Institute Of Technology Method for the synthesis of pyrrole and imidazole carboxamides on a solid support
US6635417B1 (en) 1996-07-31 2003-10-21 California Institute Of Technology Complex formation between DSDNA and oligomer of cyclic heterocycles
US6506906B1 (en) 1996-02-26 2003-01-14 California Institute Of Technology Preparation and use of bifunctional molecules having DNA sequence binding specificity
US6143901A (en) * 1996-07-31 2000-11-07 Genesoft, Inc. Complex formation between dsDNA and pyrrole imidazole polyamides
EP1023288A1 (en) 1996-02-26 2000-08-02 California Institute Of Technology Stereochemical control of the dna binding affinity, sequence specificity, and orientation-preference of chiral hairpin polyamides in the minor groove
US5998140A (en) 1996-07-31 1999-12-07 The Scripps Research Institute Complex formation between dsDNA and oligomer of cyclic heterocycles
GB9623522D0 (en) * 1996-11-11 1997-01-08 Pharmacia & Upjohn Spa Benzoheterocycle distamycin derivatives process for preparing them and their use as antitumour and antiviral agents
GB9806692D0 (en) 1998-03-27 1998-05-27 Pharmacia & Upjohn Spa Benzoheterocyclic distamycin derivatives, process for preparing them and their use as antitumour agents
GB9816652D0 (en) * 1998-07-30 1998-09-30 Pharmacia & Upjohn Spa Sulfurated distamycin derivatives process for preparing them and their use as antitumor agents
US6559125B1 (en) 2000-01-28 2003-05-06 California Institute Of Technology Polyamide-alkylator conjugates and related products and method
CN1427839A (en) 2000-03-16 2003-07-02 根索福特股份有限公司 Charged compounds comprising nucleic acid binding moiety and uses therefor
US7078536B2 (en) 2001-03-14 2006-07-18 Genesoft Pharmaceuticals, Inc. Charged compounds comprising a nucleic acid binding moiety and uses therefor
WO2002088119A1 (en) 2001-04-26 2002-11-07 Genesoft Pharmaceuticals, Inc Halogen-substituted thienyl compounds
US20030236198A1 (en) 2001-06-13 2003-12-25 Genesoft, Inc. Antipathogenic benzamide compounds
EP1539151B1 (en) 2002-08-02 2009-03-18 Genesoft Pharmaceuticals, Inc. Biaryl compounds having anti-infective activity
CA2503119A1 (en) 2002-10-25 2004-05-13 Genesoft Pharmaceuticals, Inc. Anti-infective biaryl compounds
JP2006509027A (en) 2002-12-10 2006-03-16 オーシェント ファーマシューティカルズ コーポレーション Antibacterial compound having (pyrrolecarboxamide)-(benzamide)-(imidazolecarboxamide) motif

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8612218D0 (en) * 1986-05-20 1986-06-25 Erba Farmitalia Site specific alkylating agents
GB8906709D0 (en) * 1989-03-23 1989-05-10 Creighton Andrew M Acryloyl substituted pyrrole derivatives
IT1262921B (en) * 1992-01-10 1996-07-22 Federico Arcamone ANALOGUE AGENTS ANALOGUES OF PYROL-AMIDINE OLIGOPEPTIDES BACK TO PREPARATION PROCESSES AND PHARMACEUTICAL PRODUCTS CONTAINING THEM

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO9420463A1 *

Also Published As

Publication number Publication date
CA2157187A1 (en) 1994-09-15
IT1271456B (en) 1997-05-28
ITFI930030A0 (en) 1993-03-01
ITFI930030A1 (en) 1994-09-01
KR960701007A (en) 1996-02-24
JPH08508720A (en) 1996-09-17
AU6206894A (en) 1994-09-26
WO1994020463A1 (en) 1994-09-15

Similar Documents

Publication Publication Date Title
WO1994020463A1 (en) Novel distamycin analogues
EP0667854B1 (en) Peptidyl activated ketone inhibitors containing natural and unnatural peptide sequences
AU723360B2 (en) Substituted cyclopentane compounds useful as neuraminidase inhibitors
JPH0471920B2 (en)
PT101027A (en) Process for their preparation and their use as pharmaceutical compositions
SK50294A3 (en) Peptide analogues as irreversible inhibitors of interleukin 1-beta-proteasis
RU2069662C1 (en) Derivatives of pyrazolo-[1,5-a]-pyridine or their pharmaceutical acceptable salts and method of their synthesis
WO1991008195A1 (en) N-(1-(2-carboxyethyl)cycloalkyl carbonyl)-beta-alanine derivatives for pharmaceutical use
HU220073B (en) Acyl derivatives of aryl-alkyl-amins with antihypertensive activity and pharmaceutical compositions comprising them
US6509359B1 (en) Pyrrolidin-2-one compounds and their use as neuraminidase inhibitors
JP2002508389A (en) Anti-picornavirus compounds and methods for their use and production
AU626361B2 (en) Retroviral protease inhibitors
AU713863B2 (en) Aryl acrylic acid derivatives useful as protein tyrosine phosphatase inhibitors
EP1100778B1 (en) Oxidised sulfurated distamycin derivatives, process for preparing them, and their use as antitumor agents
JP2004535459A (en) Compound having prolyl oligopeptidase inhibitory activity, production method thereof and use thereof
EP0555479B1 (en) Epoxysuccinamic acid derivative
PL167915B1 (en) Method of obtaining n-(alpha-substituted pyridinyl) carbonyl dipeptide hypertensors
NZ260063A (en) Aromatic derivatrives of 2,4-diamino-3-hydroxy carboxylic acid amides; and medicaments thereof
JPH06179649A (en) Amino acid derivative and enkephalinase inhibitor comprising the same derivative as active ingredient
US20070082922A1 (en) Huperzine a prodrugs and uses thereof
US20210122772A1 (en) Pentafluorophosphate derivative, its uses and an appropriate manufacturing method
US20060229254A1 (en) Compounds having prolyl oligopeptidase inhibitory activity
EP0309261B1 (en) Butenoic acid amides, their salts, pharmaceutical compositions containing them and process for preparing same
JP4659843B2 (en) Novel derivatives of phosphinicaminoacids, process for their production and pharmaceutical compositions containing them
WO1988009785A1 (en) Butenoic acid amides, their salts, pharmaceutical compositions containing them and process for preparing same

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19950925

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LI LU MC NL PT SE

17Q First examination report despatched

Effective date: 19970113

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 19970325